Business Context and Reporting Period
This Form 8-K Current Report was filed by Nemus Bioscience, Inc. (noted as Skye Bioscience, Inc. in metadata) on December 14, 2015. The filing discloses the entry into material definitive agreements regarding intellectual property licensing.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. Financial impact is limited to the terms of the new agreements:
- Upfront Fees: The Company paid upfront license fees to the University of Mississippi (UM) under two agreements, though specific amounts are not disclosed in this text.
- Milestone Payments: Aggregate contingent milestone payments total $1.4 million upon achievement of development and regulatory milestones.
- Royalties: Potential royalty percentage is in the high-single digits on net sales of licensed products.
- Annual Maintenance Fees: Required annually and credited against royalties in the current fiscal year.
Material Changes
The primary material change is the acquisition of exclusive, perpetual licenses for UM8930, a pro-drug formulation of Cannabidiol, developed by the University of Mississippi, School of Pharmacy. The Company secured rights for:
- Ocular delivery.
- Rectal delivery.
- An option for rights to use UM8930 for other delivery means, renewable every six months.
Outlook, Risks, and Contingencies
Management Commentary and Obligations: The Company has identified target indications for development and commercialization. The agreements include obligations to pay a portion of licensing fees received from sublicensees to UM, subject to a minimum royalty.
Risks and Termination: UM may terminate the agreements if the Company fails to pay material amounts, materially breaches covenants, fails to comply with terms, undergoes bankruptcy, dissolves, or fails to make reasonable efforts to commercialize at least one product within one year of the first commercial sale. The Company may terminate with 60 days' written notice.
Duration: Licenses continue until the later of patent expiration or the end of payment obligations. Royalty obligations end upon the later of patent expiration in a given country or ten years after the first commercial sale in that country.
Investor Verification Checklist
- Verify the specific amount of upfront license fees paid to the University of Mississippi.
- Confirm the specific "high-single digit" royalty percentage in the full text of Exhibits 10.1 and 10.2.
- Review the detailed development and regulatory milestones required to trigger the $1.4 million in payments.
- Assess the Company's current cash position to ensure it can meet annual maintenance fees and future milestone obligations.
- Examine the confidential portions of the exhibits filed separately with the SEC for omitted financial terms.